EQL Pharma Reports Q2 2026/2027 Financial Results

EQL Pharma reported a rebound in sales and EBITDA in the second quarter of fiscal 2026/2027, supported by temporary demand following stock-outs and a milestone payment related to Mellozzan. Write-downs weighed on gross margin. Management maintained its full-year growth guidance of 15%, while saying recovery depends on reliable supply chains and better execution of product launches.